NMN — The Verdict

The VerdictLOW CONVICTIONWorth-It: Low ROI (44/100)

NMN raises NAD+ in your blood exactly as advertised.

Before you buy NMN, ask one question: are you over 60 with elevated blood pressure? If yes — a third-party-verified 250–600 mg/day capsule may shave a few points off your systolic blood pressure as an adjunct to standard therapy. If no — the evidence does not support spending money on it for any other reason.

Form: β-NMN capsule (USP / NSF / ConsumerLab third-party verified). Skip sublingual, liposomal, enteric-coated.

NMN is one step away from making NAD+, a coenzyme that helps your cells generate energy and repair DNA. NAD+ levels drop as you age, and supplement marketing pitches NMN as "topping up the tank." The pump works — your blood NAD+ goes up. The car still doesn't go faster. Two large 2024–2025 reviews of human trials found that despite confirmed NAD+ rises, the outcomes people actually buy NMN for didn't change.

That's the general answer. Your stack is different.

Check your whole stack

The Protocol

The trial-grade evidence converges on a narrow capsule dose range. Above 600 mg/day, dose-response benefit flattens. Premium delivery formats lack human comparison data.

Dosing by Population

Population	Dose	Timing	Form	Source
Adults ≥60 with elevated BP (strongest indication)	250–600 mg/day	Daily, consistent	β-NMN capsule	Zhang M 2026 meta
Postmenopausal prediabetic women (Yoshino indication)	250 mg/day × ≥10 wk	Daily	β-NMN capsule	Yoshino 2021 Science
Older Japanese adults (drowsiness / 5-STS)	250 mg/day × 12 wk	Afternoon preferred	β-NMN capsule	Kim 2022
Amateur trained adults (submaximal aerobic markers)	600 mg/day	With training	β-NMN capsule	Liao 2021
Healthy adults <60 (anti-aging use)	No evidence-based dose	—	—	No matched RCT
Older adults — muscle / sarcopenia	No evidence-based dose	—	—	Prokopidis 2025 null
General adult — glucose / lipids	No evidence-based dose	—	—	Chen 2024 + Zhang J 2025 null

Practical ceiling: 600 mg/day. Yi 2023 found NAD+ elevation and 6-minute walk distance plateau at this dose. Paying for 1000+ mg products adds cost without demonstrated benefit.

Forms Comparison

β-NMN Capsule

Used in >95% of RCTs

All evidence-backed indications. Third-party verified (USP/NSF/ConsumerLab).

£20–£50/month at 250–600 mg

Sublingual NMN

No human PK data

No advantage demonstrated. Buccal-absorption claim is mechanism-plausible only.

£30–£100/month (1.2–2× premium)

Liposomal NMN

No human PK data

No advantage demonstrated. Premium pricing without outcome evidence.

£40–£150/month (1.5–3× premium)

NR (Sibling Precursor)

Same NAD+ pool

Prokopidis 2025 pooled NMN+NR for muscle endpoints — both null. Outcome data does not distinguish.

£25–£60/month at ~300 mg

Absorption notes: No clear fat / fed-state requirement. Tolerated fasted or with food. Splitting 600 mg into 2× 300 mg may reduce GI discomfort. Afternoon dosing only matters specifically for the Kim 2022 drowsiness/5-STS indication in older Japanese adults.

Safety & Interactions

Short-term safety is well-supported at the doses tested. Long-term human data is underpowered, and the regulatory grey zone created by the FDA's 2022 reclassification means product quality varies widely.

Active cancer treatment — oncology consult required

NAD+ is implicated in tumor metabolism and DNA repair. CD38 inhibitors and PARP inhibitors are NAD+-pathway oncology agents. No documented clinical interaction, but the mechanistic overlap warrants oncology discussion before use.

Stacking with other NAD+ precursors (NR, niacin, nicotinamide) — avoid

Additive load on the NAD+ salvage pathway. High-dose nicotinamide is hepatotoxic. There's no efficacy benefit demonstrated for stacking, and there is a real safety signal at high cumulative dose.

Pregnancy / lactation — not recommended

No human safety data exists. Default to avoidance until trial-grade evidence appears.

Anti-hyperglycemic drugs (metformin, insulin, sulfonylureas) — routine monitoring

If the Yoshino 2021 insulin-sensitivity signal extends to clinical populations, dose adjustment could be warranted. Current meta-analytic evidence does NOT show a glycemic effect in pooled cohorts, so practical risk is low. Keep your routine glucose monitoring.

Side Effects (across trials)

Effect	Incidence	Management
GI discomfort (nausea, bloating)	<5%	Take with food; split dose
Headache	1–3%	Often transient
Flushing	Rare at NMN doses	Distinct from niacin flush
Serum chemistry shifts (bilirubin, creatinine)	Within normal ranges (Irie 2020)	No action required

Upper Limit

Tolerable Upper Intake Level: Not established (no regulatory body has issued a UL).
Highest dose tested safely: 1250 mg/day × 4 weeks (Fukamizu 2022); 900 mg/day × 60 days (Yi 2023).
Long-term (>6 months) safety: Limited. Akasaka 2023 ran 24 weeks at 250 mg in 14 older diabetic men with no adverse events. Nothing in the literature runs ≥12 months.
Theoretical long-term concerns: Methylated-metabolite accumulation, tumorigenesis risk, senescence promotion at supraphysiological NAD+ — flagged in Braidy & Liu 2020 review, not ruled out by adequately powered long-duration human trials.

Conviction

LOW-to-MODERATE

Conviction is endpoint-stratified — high for the biomarker (NAD+ elevation) and short-term safety; low or null for most outcome claims that drive consumer purchases.

Endpoint	Conviction
NAD+ blood elevation at 250–1250 mg/day	HIGH
Short-term safety (≤4 wk at 1250 mg; ≤60 days at 900 mg)	HIGH
DBP reduction in adults with elevated BP	MODERATE
SBP reduction in ≥60 subgroup with elevated BP	MODERATE
Submaximal aerobic markers (amateur trained adults)	MODERATE
Muscle insulin sensitivity (postmenopausal prediabetic women)	LOW
Biological age / SF-36 / walking distance (Yi 2023)	LOW
Glucose / HbA1c / lipids (general adults)	DEBUNKED
Sarcopenia (older adults — Prokopidis null)	DEBUNKED
Cognition / Alzheimer's prevention	NONE
Mortality / hard CV events / longevity	NONE
Healthy-adult under-60 anti-aging use	NONE
NMN superiority over NR	NONE
Sublingual / liposomal advantage	NONE

What would change this verdict?

Upgrade muscle / sarcopenia to MODERATE: A pre-registered multi-center RCT of ≥400 community-dwelling older adults with confirmed sarcopenia, randomized to 600 mg/day NMN vs placebo for ≥12 months, with primary endpoints SPPB and grip strength, showing ≥0.5 SD effect.

Upgrade metabolic outcomes to MODERATE: A pre-registered RCT of ≥200 adults with confirmed prediabetes, 250–600 mg/day for ≥6 months, primary endpoint HbA1c reduction ≥0.3%.

Upgrade healthy-adult prophylactic use above null: Any RCT (N ≥200) in healthy 35–55-year-olds with a hard physiological or functional primary endpoint (not SF-36 or aging-calculator surrogates), showing ≥6-month benefit. This trial does not currently exist.

Upgrade long-term safety to HIGH: A prospective cohort or RCT of ≥1000 adults on NMN for ≥24 months with active adverse-event surveillance and cancer-incidence tracking. Current human safety evidence is short-duration and underpowered for rare events.

Worth Your Money?

Weekly cost£5–£12 per week — one or two standard capsules per day, third-party verified

Worth it ifYou're 60 or older with elevated blood pressure, already on standard BP therapy, and want to add a small adjunct effect (a few mmHg SBP reduction). Or you're a postmenopausal woman with diagnosed prediabetes working with a clinician on muscle insulin sensitivity.

Lower priority ifYour sleep is inconsistent, your training basics are unreliable, your protein intake is low, or your blood pressure isn't elevated. The next £30 is almost certainly better spent on improving sleep, training consistency, or having your BP measured properly than on adding NMN. NMN is not a substitute for any of those.

Conditional Value

Sources

Chen F et al. (2024). Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of RCTs. Curr Diab Rep. PMID 39531138. N=342 across 8 RCTs. No significant effect on FG, insulin, HbA1c, HOMA-IR, lipids.
Zhang J et al. (2025). Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis. Crit Rev Food Sci Nutr. PMID 39116016. N=513 across 12 RCTs. NAD+ elevated; most clinical outcomes NS. Authors state "an exaggeration of the benefits of NMN supplementation may exist in the field."
Prokopidis K et al. (2025). The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis. J Cachexia Sarcopenia Muscle. PMID 40275690. Mean age 60.9–83. No significant effect on SMI, HGS, gait speed, 5CST.
Zhang M et al. (2026). Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of RCTs. Nutrients. PMID 41901064. N=349, 10 RCTs. DBP −2.15 mmHg; SBP NS overall, −3.94 mmHg in ≥60 subgroup.
Yoshino M et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. PMID 33888596. NCT03151239. 250 mg/day × 10 wk. Muscle insulin sensitivity increased.
Yi L et al. (2023). Efficacy and safety of β-NMN supplementation in healthy middle-aged adults: dose-dependent clinical trial. GeroScience. PMID 36482258. NCT04823260. N=80 × 60 days. NAD+ dose-dependent rise; 6MWD improved. Industry-associated authors.
Liao B et al. (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. J Int Soc Sports Nutr. PMID 34238308. N=48, 4 arms × 6 wk. VT1 / VT2 improved; VO2max peak unchanged.
Fukamizu Y et al. (2022). Safety evaluation of β-NMN oral administration in healthy adults. Sci Rep. PMID 36002548. N=31. 1250 mg/day × 4 wk. Safe and well-tolerated.
Braidy N, Liu Y (2020). NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis. Exp Gerontol. PMID 31917996. 147 studies. Flags theoretical long-term risks.
Alghamdi M, Braidy N (2024). Supplementation with NAD+ Precursors for Treating Alzheimer's Disease. J Alzheimers Dis. PMID 39422945. Zero human NMN-in-AD trials identified.

Action ROI

Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.

Action ROI score

44/100 Low ROI Trust grade D

No - for healthy aging there is no human outcome evidence, only a biomarker that goes up.

Time

Low

Money

Medium

Effort

Low

Risk

Low

Why this score

The headline goal fails on evidence: two large 2024 to 2025 meta-analyses (Chen 2024, N=342; Zhang J 2025, N=513) found no significant effect on glucose, HbA1c, insulin resistance, or lipids despite confirmed NAD+ elevation, and Zhang J 2025 wrote that 'an exaggeration of the benefits of NMN supplementation may exist in the field.'
No longevity benefit exists to leverage: zero trials measure mortality, hard CV events, or validated epigenetic age, and there is no matched RCT in healthy adults under 60 for any outcome.
Money cost is Medium and stings for nothing: about $25 to $63 a month for a verified capsule, with no food source, while sleep, training, and weight management drive the same NAD+ and sirtuin biology for free.
Trust grade is D: the most-cited positive consumer trial (Yi 2023, N=80) used soft endpoints like SF-36 and an aging-calculator and has industry-adjacent authors, with no independent replication.
Risk is Low at the dose (safe to 1250 mg/day for 4 weeks, Fukamizu 2022), but long-term safety past 6 months is untested and three theoretical concerns (metabolite buildup, tumorigenesis, senescence) remain unresolved.

Why it didn’t score higher

The entire purchase rationale for this audience - slower aging - has no human outcome evidence, so even a perfect safety profile cannot lift it.
The one real signal (a 3.94 mmHg systolic drop in adults over 60, Zhang M 2026, N=349) is the wrong outcome for the longevity goal and the wrong age group for most buyers.
Label-accuracy is so poor post-2022 that real-world effect is likely smaller than even the null trials suggest.

Best for

Adults 60 and over with elevated blood pressure who want a low-risk adjunct to standard therapy and accept thin evidence (the only defensible use, and not a longevity claim)
Postmenopausal women with prediabetes pursuing the narrow Yoshino 2021 insulin-sensitivity signal at 250 mg/day for 10+ weeks, knowing it rests on one landmark RCT

Lower ROI if

You are a healthy adult under 60 buying for anti-aging - no matched trial exists
You are an older adult expecting muscle or sarcopenia benefit (Prokopidis 2025 is null)
You buy premium sublingual or liposomal forms, which have no human comparison data
You will not pay for third-party-verified product

Minimum effective dose

250 to 600 mg/day of a third-party-verified beta-NMN capsule. Benefit plateaus at about 600 mg/day, so 1000+ mg products add cost without demonstrated advantage. For the healthy-aging goal there is no evidence-based dose at all.

Track this

Honestly, nothing reliable for the longevity goal - no validated acute marker tracks anti-aging benefit
Home blood pressure over 8 to 12 weeks only if you are in the over-60 elevated-BP subgroup
Third-party certificate of analysis on the actual bottle you bought (USP, NSF, or ConsumerLab)